Bronchopulmonary dysplasia（BPD）is a significant complication that greatly impacts the prognosis of preterm infants.The incidence of pulmonary hypertension（PH）in preterms with moderate to severe BPD is relatively high，which further increases the mortality among infants with BPD.Diagnosis of BPD could be made until 36 weeks corrected gestational age，and the clinical manifestations of BPD-PH are also not specific enough for accurate identification.Cardiac catheterization is considered the gold standard for diagnosis，which is an invasive procedure，while echocardiography heavily relies on the experience of operator，limiting early detection of both BPD and BPD-PH.N-terminal pro-brain natriuretic peptide（NT-proBNP），secreted by ventricular myocytes in response to volume or pressure overload，has been widely utilized in assessing cardiac load in cases of congenital heart disease.Recent studies have shown that the blood NT-proBNP levels significantly elevate in infants with BPD within one week after birth and during the development stage of BPD.Additionally，there is a substantial increase in NT-proBNP levels from 28 to 36 weeks corrected gestational age，which has both high sensitivity and high specificity in predicting the occurrence of BPD-PH.Therefore，NT-proBNP is expected to serve as a biomarker for the early prediction of BPD and BPD-PH.This review summarized the biological function，metabolic characteristics，and current research advancements regarding NT-proBNP in BPD and BPD-PH.The aim is to utilize NT-proBNP as an early predictor for BPD and BPD-PH，enabling timely identification of premature infants with high risk factors of these diseases，and facilitating prompt intervention to ultimately enhance prognosis.